Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

A comparison between Pap and HPV screening tests and screening methods.

Altobelli E, Scarselli G, Lattanzi A, Fortunato C, Profeta VF.

Mol Clin Oncol. 2016 Aug;5(2):348-354. Epub 2016 May 23.

2.

Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.

Clifford GM, Vaccarella S, Franceschi S, Tenet V, Umulisa MC, Tshomo U, Dondog B, Vorsters A, Tommasino M, Heideman DA, Snijders PJ, Gheit T.

J Clin Microbiol. 2016 Aug;54(8):2031-8. doi: 10.1128/JCM.00618-16. Epub 2016 May 25.

PMID:
27225411
3.

Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens.

Toliman P, Badman SG, Gabuzzi J, Silim S, Forereme L, Kumbia A, Kombuk B, Kombati Z, Allan J, Munnull G, Ryan C, Vallely LM, Kelly-Hanku A, Wand H, Mola GD, Guy R, Siba P, Kaldor JM, Tabrizi SN, Vallely AJ.

J Clin Microbiol. 2016 Jul;54(7):1734-7. doi: 10.1128/JCM.00529-16. Epub 2016 Apr 13.

PMID:
27076663
4.

The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.

Naber SK, de Kok IM, Matthijsse SM, van Ballegooijen M.

Cancer Causes Control. 2016 Apr;27(4):569-81. doi: 10.1007/s10552-016-0732-7. Epub 2016 Mar 12.

5.

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AG, Schuuring E, Wisman GB.

Clin Epigenetics. 2016 Mar 9;8:29. doi: 10.1186/s13148-016-0196-3. eCollection 2016.

6.

Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Burd EM.

Clin Microbiol Rev. 2016 Apr;29(2):291-319. doi: 10.1128/CMR.00013-15. Review.

PMID:
26912568
7.

Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.

Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M.

PLoS One. 2016 Jan 29;11(1):e0145548. doi: 10.1371/journal.pone.0145548. eCollection 2016.

8.

Validation of a DNA methylation HPV triage classifier in a screening sample.

Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J, Vasiljević N.

Int J Cancer. 2016 Jun 1;138(11):2745-51. doi: 10.1002/ijc.30008. Epub 2016 Feb 8.

9.

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E.

PLoS One. 2016 Jan 20;11(1):e0147326. doi: 10.1371/journal.pone.0147326. eCollection 2016.

10.

Clinical significance of human papillomavirus genotyping.

Choi YJ, Park JS.

J Gynecol Oncol. 2016 Mar;27(2):e21. doi: 10.3802/jgo.2016.27.e21. Review.

11.

The role of human papillomavirus testing after treatment for high-grade cervical dysplasia.

Turner TB, Huh WK.

J Gynecol Oncol. 2016 Jan;27(1):e9. doi: 10.3802/jgo.2016.27.e9. Epub 2015 Dec 3. No abstract available.

12.

Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.

Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M.

BMC Cancer. 2015 Dec 16;15:968. doi: 10.1186/s12885-015-1959-5.

14.

Screening of cervical cancer in Catalonia 2006-2012.

de Sanjosé S, Ibáñez R, Rodríguez-Salés V, Peris M, Roura E, Diaz M, Torné A, Costa D, Canet Y, Falguera G, Alejo M, Espinàs JA, Bosch FX.

Ecancermedicalscience. 2015 Apr 29;9:532. doi: 10.3332/ecancer.2015.532. eCollection 2015.

15.

Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm.

Chang CC, Huang RL, Liao YP, Su PH, Hsu YW, Wang HC, Tien CY, Yu MH, Lin YW, Lai HC.

BMC Cancer. 2015 May 19;15:418. doi: 10.1186/s12885-015-1411-x.

16.

Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda.

Sinayobye Jd, Sklar M, Hoover DR, Shi Q, Dusingize JC, Cohen M, Mutimura E, Asiimwe-Kateera B, Castle PE, Strickler H, Anastos K.

Infect Agent Cancer. 2014 Dec 8;9:40. doi: 10.1186/1750-9378-9-40. eCollection 2014.

17.

Major clinical research advances in gynecologic cancer in 2014.

Suh DH, Lee KH, Kim K, Kang S, Kim JW.

J Gynecol Oncol. 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. Review.

18.

Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia.

Park IU, Wojtal N, Silverberg MJ, Bauer HM, Hurley LB, Manos MM.

PLoS One. 2015 Mar 20;10(3):e0118938. doi: 10.1371/journal.pone.0118938. eCollection 2015.

19.

Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, Constantinidis TC; HERMES study group.

PLoS One. 2015 Mar 20;10(3):e0119755. doi: 10.1371/journal.pone.0119755. eCollection 2015.

20.

Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.

Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, Minucci D, Rosso S, Zorzi M, Naldoni C, Segnan N, Confortini M, Ronco G.

J Natl Cancer Inst. 2015 Jan 7;107(2). pii: dju423. doi: 10.1093/jnci/dju423. Print 2015 Feb.

Items per page

Supplemental Content

Write to the Help Desk